Lee, M. Y., Byrnes, J. J., Downey, K. M., So, A. G. 1980 ; Mechanism of inhibition of deoxyribonucleic acid synthesis by triphosphate and its potentiation by 6-mercaptopurine ribonucleoside 5'-monophosphate, Biochemistry, 19, 215-219. Lennard, L. 1992 ; The clinical pharmacology of 6-mercaptopurine, Eur J Clin Pharmacol, 43, 329-339. Lennard, L. 2002 ; TPMT in the treatment of Crohn's disease with azathioprine, Gut, 51, 143146. Lennard, L., Hale, J. P., Lilleyman, J. S. 1993 ; Red blood cell hypoxanthine phosphoribosyltransferase activity measured using 6-mercaptopurine as a substrate: a population study in children with acute lymphoblastic leukaemia, Br J Clin Pharmacol, 36, 277-284. Lennard, L., Lilleyman, J. S. 1989 ; Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia, J Clin Oncol, 7, 1816-1823. Lennard, L., Lilleyman, J. S., Van Loon, J., Weinshilboum, R. M. 1990 ; Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia, Lancet, 336, 225-229. Lennard, L., Maddocks, J. L. 1983 ; Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells, J Pharm Pharmacol, 35, 15-18. Lennard, L., Van Loon, J. A., Lilleyman, J. S., Weinshilboum, R. M. 1987 ; Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations, Clin Pharmacol Ther, 41, 18-25. Lennard, L., Van Loon, J. A., Weinshilboum, R. M. 1989 ; Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism, Clin Pharmacol Ther, 46, 149-154. LePage, G. A., Whitecar, J. P., Jr. 1971 ; Pharmacology of 6-thioguanine in man, Cancer Res, 31, 1627-1631. Lesch, M., Nyhan, W. L. 1964 ; A Familial Disorder Of Uric Acid Metabolism And Central Nervous System Function, J Med, 36, 561-570. Li, W., Fan, J., Hochhauser, D., Banerjee, D., Zielinski, Z., Almasan, A., et al. 1995 ; Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines, Proc Natl Acad Sci U S A, 92, 10436-10440. Li, W. W., Lin, J. T., Tong, W. P., Trippett, T. M., Brennan, M. F., Bertino, J. R. 1992 ; Mechanisms of natural resistance to antifolates in human soft tissue sarcomas, Cancer Res, 52, 1434-1438. Li, W. W., Waltham, M., Tong, W., Schweitzer, B. I., Bertino, J. R. 1993 ; Increased activity of gamma-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate MTX ; , Adv Exp Med Biol, 338, 635-638. Liani, E., Rothem, L., Bunni, M. A., Smith, C. A., Jansen, G., Assaraf, Y. G. 2003 ; Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines, Int J Cancer, 103, 587-599. Lilleyman, J. S., Lennard, L. 1994 ; Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia, Lancet, 343, 1188-1190. Lin, J. T., Tong, W. P., Trippett, T. M., Niedzwiecki, D., Tao, Y., Tan, C., et al. 1991 ; Basis for natural resistance to methotrexate in human acute non-lymphocytic leukemia, Leuk Res, 15, 1191-1196 and trileptal. CONCLUSION The potential use of anthrax as a biological weapon has renewed interest in the clinical presentation and treatment of this infectious disease. Recognizing the clinical presentation, diagnosing, reporting, and treating casualties of biological warfare are developing responsibilities for the NP. It is important for NPs to stay informed of developing technology aimed at prevention and protection against anthrax, and the potential of terrorist activity in metropolitan areas, port cities, military installations, and rural communities. Knowledge of local emergency and disaster plans is important for prompt and efficient response to an intentional or unintentional release of B. anthracis. Methods for procurement of antibiotics and vaccines in case of mass casualties must be part of the disaster plan. Disease reporting protocols for suspected and diagnosed infectious disease should be readily available. Despite the best efforts of NPs and other health care providers, the consequences of an intentional release of anthrax could result in a public health disaster. The knowledgeable and immediate response of NPs in the event of an intentional release of aerosolized anthrax will control public panic and minimize morbidity and mortality. References. Flora of the C arolinas, Virginia, and Georgia, W orking D raft of 10 June 2005 -- D R YO RID A CE AE vascular bundles in the petiole either 2 or 4-7. 6 Leaf blades pentagonal or broadly triangular in outline, ca. 1 as long as wide. 7 Leaf blade pentagonal in outline, the term inal pinna by far the largest; rhizom e 5-8 m m in diam eter; indusia present, thick, persistent, and reniform ; vascular bundles in the low er petiole 4-7; [introduced species, naturalized in m oist ravines in SC ]; [subfam ily D ryopteridoideae, tribe D ryopterideae] . rachniodes 7 Leaf blade broadly triangular in outline, the basal pinnae by far the largest; rhizom e ca. 1 m m diam eter; indusia absent; vascular bundles in the lower petiole 2; [native species of m ountain peaks of n. N and VA ]; [subfam ily Athyrioideae, tribe Physem atieae] . nocarpium 6 Leaf blades lanceolate, oblong, or ovate in outline, 2 or m ore as long as wide. 8 Leaves 1-pinnate, the pinnae toothed and each with a slight to prom inent lobe near the base on the side towards the leaf tip, dark green, subcoriaceous to coriaceous; indusia peltate; [subfam ily D ryopteridoideae, tribe D ryopterideae]. 9 V eins anastam osing, rejoining to form a netlike pattern; pinnae 4-25 pairs per leaf; [non-native, rarely naturalized] . Cyrtom ium 9 Veins branching dichotom ously, free, not rejoining to form a netlike pattern; pinnae 25-50 pairs on larger leaves; [plant a com m on native species] . Polystichum 8 Leaves 1-pinnate-pinnatifid to m ore divided, the pinnae pinnatifid or them selves fully divided, generally lacking a prom inent basal lobe, light green to dark green, herbaceous to subcoriaceous; indusia reniform , cuplike, or lateral. 10 Indusia reniform ; vascular bundles in the lower petiole 4-7; plants m edium to large, the larger leaf blades 23-100 cm long, 8- ; 10-40 cm wide; [subfam ily D ryopteridoideae, tribe D ryopterideae] . ryopteris 10 Indusia hoodlike, pocketlike, cuplike, or consisting of num erous hairs attached below the sorus; vascular bundles in the lower petiole 2; plants sm all to m edium , the larger leaf blades 5-65 cm long, 1.5-12 cm wide som etim es longer or wider in C ystopteris bulbifera, distinguishable by its long-attenuate leaf tip and bulblets [subfam ily Athyrioideae, tribe Physem atieae]. 11 Indusium attached under one side of the sorus, hoodlike or pocketlike, arching over the sorus; petioles glabrous or sparsely beset with scales, the petiole bases not persistent . ystopteris 11 Indusium attached under the sorus, cuplike divided into 3-6 lanceolate to ovate lobes which surround the sorus from below ; or of m inute num erous septate hairs, which extend out from under the sorus on all sides; petioles often densely beset with scales, the petiole bases persistent . oodsia and antabuse.

185. Tang H, Neuberger J: Review article: Metohtrexate in gastroenterology-dangerous villain or simply misunderstood? Aliment Pharmacol Ther 10: 851-858, 1996 Tarazi EM, Harter JG, Zimmerman 11J, et al: Sulinclacassociated hepatic injury: Analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology 104: 569574, 1993 Teitelbaum JE, Perez-Ataycle AR, Cohen M, et al: Minocycline-related autoimmune hepatitis: Case series and literature review. Arch Pediatr Adolesc Med 152: 11321136, 1998 Trauner M, Meier 1 , Boyer JL: Molecular pathogenesis of cholestasis. N Engl J Med 339: 1217-1227, 1998 Ungo JR, Jones D, Ashkin D, et al: Antituberculosis druginduced hepatotoxicity: The role of hepatitis C virus and the human immunodeficiency virus. J Respir Crit Care Med 157 6 pt 1 ; 1871-1876, 1998 190. Valla D, Benhamou ; P: Drug-induced vascular and sinusoidal lesions of the liver. Baillieres Clin Gastroenterol 2: 481, 1988 Wang BH, Zuzel KA, Rhaman K, et al: Treatment with aged garlic extract protects against bromobenzene toxicity to precession cut rat liver slices. Toxicology 132: 277282, 1999 Watkins PB, Whitcomb RW: Hepatic dysfunction associated with Troglitazone [letter]. N Engl J Med 338: 916-917, 1998 Watkins PB, Zimmerman H ; , Knapp HJ, et al: Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. ; AMA 271: 992-998, 1994 Watson RGP, Olomu A, Clements D, et al: A proposed mechanism for chlorprornazine jaundic"efective hepatic sulphoxiclation combined with rapid hydroxylation. J Hepatol 7: 72-78, 1988 Weiss JC, Layden T, Spinowitiz A, et al: Chronic active hepatitis associated with etretinate therapy. Br J Dermatol 112: 591-597, 1985 Whitcomb DC, Block GD: Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 272: 18451849, 1994 Whitehead MK Hawkes ND, Hainsworth 1, et al: A prospective study of the causes of notably raised aspartate aminotransferase of liver origin. Gut 45: 129-133, 1999 Wong WM, Wu PC, Yuen MF, et al: Antituberculosis drugrelated liver dysfunction in chronic hepatitis B infection. Hepatology 31: 201-206, 2000 Wright C IV, Vafier JA, Lake CR: Disulfiram-incluced fulminant hepatifis: Guidelines for liver-panel monitoring. J Clin Psychiatry 49: 430-434, 1988 Yamazaki H, Shibata A, Suzuki M, et al: Oxidation of troglitazone to a quinone-" metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos 27: 1260-1266, 1999 Yao F, Behling CA, Saab S, et al: vanishing bile duct syndrome. J GastroLnterol 92: 167-169, 1997 Zafrani E, Pinaudeau Y, Dhun-.eaux D: Drug-induced vascular lesions of the liver. Arch Intern Med 143: 495-502, 1983 Zafrani ES, Ishak KG, Rudzki C: Cholestatic and hepatocellular injury associated with erythromycin esters: Report of 9 cases. Dig Dis Sci 24: 385-396, 1979 Zimmerman HJ: Effects of aspirin and acetaminophen on the liver. Arch Intern Med 141: 333, 1981 Zimmerman HJ: Effects of alcohol on other hepatotoxins. Alcohol Clin Exp Res 10: 3, 1986 Zimmerman [I: Even isoflurane. Hepatology 13: 1251-1253, 1991 Zimmerman I ij: Acetaminophen hepatotoxicity. Clin Liver Dis 2: 523-541, 1998.
4 38 ; . However, the transport properties of NPT1 do not fit with the results from membrane vesicle studies, and there is no direct evidence that hUAT1 transports urate. So far, a candidate for the efflux step in human urinary urate excretion has not been identified. Studies with mouse L1210 cells have identified multiple ATP-dependent export pumps for methotrexate MTX ; , sharing urate as a substrate 12 ; . Furthermore, in human erythrocytes an ATP-dependent urate transporter has been described 22 ; . The characteristics of these transporters resemble members of the multidrug resistance protein MRP ; family, of which MRP1, MRP4, MRP5 are expressed in erythrocytes 18 ; . MTX is a substrate for MRPs 1-4 3; 20 ; , and various endogenous cAMP and cGMP ; and xenobiotic nucleosides are substrates for MRP4 6; 25; 40 , MRP5 15; 25; 42-44 ; , and MRP8 10 ; . Since MRP2 and MRP4 are the only members expressed at the apical membrane of kidney proximal tubules 32; 40 ; , we investigated the interaction of urate with MRP2 and MRP4. In this study, we show that human MRP4 mediates ATP-dependent urate transport through multiple allosteric binding sites, whereas urate is not a substrate for human MRP2 and lariam.
1. Coverage will not be provided for the following conditions: actinic lentigines, actinic skin damage, photoactinic damage, photodamaged skin alopecia chloasma cutis laxa cysts dermatoheliosis dyschromia elastosis, solar elastosis, senile elastosis hyperpigmentation keloids, scars keratosis pilaris, keratosis seborrhea, keratosis stucco lentigines melasma milia nevus. Morales, A., Condra, M., Owen, J. A., Surridge, D. H., Fenemore, J., Harris, C. Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial. 1987 Pts: 100 Controlled Trial: Controlled with partial crossover Ontario, Carnada Ext: AJM Yohimbine Pt. Desc: organic 100%, Placebo pts who subsequently got yohimbine Pt. Desc: organic 100%, age: 56 18, 70 ; age: 18, 70 ; duration: Rx: duration: Rx: Pts: yohimbine 18 Pts: yohimbine 18 and pletal.

In addition to funding research, NIAID collaborates extensively with other NIH Institutes and Centers, as well as with private organizations. The Institute supports and co-sponsors conferences, meetings, and workshops. The Institute communicates not only research results to scientists through workshops and conferences, but also medical information to the public and to physicians through its Office of Communications and Public Liaison. Every year, approximately 12, 000 people call NIAID for information, and thousands more write for copies of pamphlets and other materials.

Body weight a ; Has your weight fluctuated more than a few kilos in the last 12 months? Yes No. b ; If `Yes', approximately how many kilograms? and cyklokapron and Order methotrexate. AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY comorbid anxiety disorders DuPaul et al., 1994; Livingston et al., 1992 ; . In one sample, although methylphenidate reduced activity level in children with ADHD and anxiety, working memory improved in children with ADHD only, but not in those with comorbid anxiety. There was no stimulant-related decrement in performance Tannock et al., 1995 ; . Pliszka 1989 ; found fewer stimulant responders among ADHD subjects with comorbid anxiety, and some had a placebo response as large as the stimulant response Pliszka, 1989 ; . In that sample, none of the ADHD children with anxiety worsened on stimulant medication. Other studies have found that children with comorbid anxiety respond as well as those without Gadow et al., 1995; Livingston et al., 1992 ; . Among mentally retarded children with ADHD, higher parent ratings of impulsivity and activity and higher teacher ratings of activity, impulsivity, inattention, and conduct problems predict greater positive response to stimulants. Laboratory measures of behavior have relatively poor predictive utility for medication response Handen et al., 1994 ; . Children with an IQ of less than 45 are much less likely to have a clinically significant positive response Aman et al., 1991 ; . In children and adolescents with mental retardation and ADHD, stimulants reduce target symptoms of inattention, impulsivity, and overactivity Aman et al., 1993a, 1993b; Handen et al., 1990; Handen et al., 1992; Varley and Trupin, 1982 ; . Measures of learning and social interactions did not appear to improve in these children, however Handen et al., 1992 ; . No patient characteristics are helpful in suggesting which stimulant drug is best for a particular child. Minimum ages approved by the Federal Drug Administration are not based on clinical or research data. Methylphenidate is the most commonly used and best studied and may be more effective in reducing motor activity than other stimulants Borcherding et al., 1989 ; . Dextroamphetamine often has a longer duration of action than methylphenidate, permitting less frequent doses or reducing gaps in medication effect between doses. Dextroamphetamine is less expensive, but it is not included in many third party formularies. Disadvantages of dextroamphetamine include negative attitudes of pharmacists, including some who are unwilling to stock it, greater risk of growth retardation Greenhill, 1991 ; , and higher potential for abuse by the patient s peers and family. Dextroamphetamine may be more likely to cause appetite suppression and compulsive behaviors. Twenty-five percent of a recent sample of ADHD boys tested on both methylphenidate and dextroamphetamine responded positively to one of the drugs but not to the other. Eighty percent of the methylphenidate non-responders were positive dextroamphetamine responders and 66% of the dextroamphetamine non-responders were positive responders to methylphenidate Elia et al., 1991 ; . Therefore, if one stimulant is insufficiently effective, another should be tried before using another drug class. Both positive and negative placebo effects have been observed in medication trials for children with ADHD Gan and Cantwell, 1982; Ullman and Sleator, 1986 ; . At times, parent, teacher, and child positive or negative drug expectancies may be so significant that a blind placebo trial is required, even in the clinical setting. This can be done at the time of initiating stimulant medication or in a placebo withdrawal paradigm to determine if medication continues to be required and effective, or is no longer needed, ineffective, or even exacerbating the condition. An individual placebo trial may also be useful in evaluating alleged stimulant side effects Ahmann et al., 1993; Barkley et al., 1990b; Fine and Johnston, 1993; Golinko, 1982 ; . Because of the short half-life of stimulants, these trials are easy to do in the clinical setting, and a number of office-based protocols have been developed Fine and Jewesson, 1989; McBride, 1988; Strayhorn, 1995; Ullmann and Sleator, 1986; Varley and Trupin, 1983 ; . Parents report greater satisfaction with this method than with typical clinical procedures Johnston and Fine, 1993.

The right to have the split samples tested if the first sample shows a prohibited substance or even a therapeutic medication with a level exceeding established thresholds. But TCO2 testing does not lend itself to split-sample testing because of the rapid dissipation of carbon dioxide from the blood samples. Even experts do not agree on how quickly this dissipation occurs, but 96 hours would seem to be the outside limit. There does not appear to be a way to test the original sample, notify the owner or trainer of the horse, and then have the split sample tested within 96 hours. We have discussed numerous alternatives, but have found none that would clearly allow the CHRB to enforce the regulation and still meet the provisions of the statute. Therefore, in order to implement the proposed regulation, the statute would need to be amended to exempt TCO2 testing from the split-sample requirement. Staff met with Derry Knight, our counsel in the Attorney General's Office, and came to an agreement on language that would amend the statute by exempting TCO2 testing. I asked Sherwood Chillingworth, executive vice president of Oak Tree, to help arrange for an author to sponsor a bill to amend the statute. He referred me to their lobbying firm, and I spoke with Anthony Gonsalves. I sent him the proposed amendment language, and he will secure an author. With an urgency provision, he estimated that if everything were to go smoothly, we could complete this matter by March or April. We also have added language that deems this an emergency for purposes of the Administrative Procedures Act. This would allow us to submit the proposed emergency regulation to OAL immediately after the governor signs any amendment to Statute 19577. It would become effective 10 days later. In the interim, TCO2 testing is continuing at Hollywood Park, which like Oak Tree, is administering the test as part of its stall allocation process. It will also continue when the Santa Anita meet starts December 26. There are drawbacks to this voluntary program in that racing associations are somewhat limited in the actions they may take against offenders, so it is important that the CHRB implement a regulation as soon as the law allows, but the testing by racing associations is a reasonable stop-gap measure. Such a testing protocol has been a standard in the harness industry in California for many years and is handled completely by the racing associations and the horsemen and zerit. Bryant J, Fisher B & Dignam J 2001 Duration of adjuvant tamoxifen therapy. Journal of the National Cancer Institute Monographs 30 5661. Buzdar A, Kau S, Smith T & Hortobagyi G 1989 Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. American Journal of Clinical Oncology 12 123128. Buzdar A, Singletary S, Theriault R, Booser D, Valero V, Ibrahim N, Smith T, Asmar L, Frye D, Manuel N, Kau S, McNeese M, Strom E, Hunt K, Ames F & Hortobagyi G 1999 Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. Journal of Clinical Oncology 1734 34123417. Buzdar A, Singletary S, Valero V, Booser D, Ibrahim N, Rahman Z, Theriault R, Walters R, Rivera E, Smith T, Holmes F, Hoy E, Frye D, Manuel N, Kau S, McNeese M, Strom E, Thomas E, Hunt K, Ames F, Berry D & Hortobagyi G 2002 Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clinical Cancer Research 8 10731079. Castiglione-Gertsch M, Johnsen C, Goldhirsch A, Gelber R, Rudenstam C, Collins J, Lindtner J, Hacking A, Cortes-Funes H & Forbes J 1994 The International Ludwig ; Breast Cancer Study Group Trials IIV: 15 years follow-up. Annals of Oncology 5 717724. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A & Crown J 1999 Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. Journal of Clinical Oncology 17 23412354. Cobleigh M, Vogel C, Tripathy D, Robert N, Scholl S, Fehrenbacher L, Wolter J, Paton V, Shak S, Lieberman G & Slamon D 1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal of Clinical Oncology 9 26392648. Curtis R, Boice J, Stovall M, Bernstein L, Greenberg R, Flannery J, Schwartz A, Weyer P, Moloney W & Hoover R 1992 Risk of leukemia after chemotherapy and radiation treatment for breast cancer. New England Journal of Medicine 326 17451751. Davidson N, O'Neill A, Vukov A, Osborne C, Martino S, White D & Abeloff M 1999 Effect of chemohormonal therapy in premenopausal, node positive, receptor positive breast cancer: an Eastern Cooperative Oncology Group Phase III Intergroup Trial E5188, INT-0101 ; . Proceedings of the American Society of Clinical Oncology Abstract 249. Diamandidou E, Buzdar A, Smith T, Frye D, Witjaksono M & Hortobagyi G 1996 Treatment-related leukemia in breast cancer patients treated with combination adjuvant chemotherapy: The University of Texas MD Anderson Cancer Center experience. Journal of Clinical Oncology 14 27222730. Early Breast Cancer Trialists' Collaborative Group 1988 Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28 896 women. New England Journal of Medicine 319 1681 1692. Early Breast Cancer Trialists' Collaborative Group 1992 Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 339 7185. Early Breast Cancer Trialists' Collaborative Group 1996 Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 348 11891196. Early Breast Cancer Trialists' Collaborative Group 1998a Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 14511467. Early Breast Cancer Trialists' Collaborative Group 1998b Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352 930942. Early Breast Cancer Trialists' Collaborative Group 2000 5th Annual Meeting of the Early Breast Cancer Trialists' Collaborative Group. Oxford UK, 2122 September, 2000. Ejlertsen B, Dombernowsky P, Mouridsen H, Kamby C, Kjaeer M, Rose C, Andersen K, Jensen M, Bengtsson N & Bergh J 1999 Comparable effect of ovarian ablation and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients. Proceedings of the American Society of Clinical Oncology Abstract 248. Feldman L, Hortobagyi G, Buzdar A, Ames F & Blumenschein G 1986 Pathologic assessment of response to induction chemotherapy in breast cancer. Cancer Research 46 25782581. Fisher B, Carbone P, Economou S, Glass A, Lerner H, Redmond C, Zelen M, Band P, Katrych D, Wolmark N & Fisher E 1975 L-Phenylalanine mustard L-PAM ; in the management of primary breast cancer: a report of early findings. New England Journal of Medicine 292 117122. Fisher B, Glass A, Redmond C, Fisher ER, Barton B, Such E, Carbone P, Economou S, Foster R, Frelick R, Lerner H, Levitt M, Margolese R, MacFarlane J, Plotkin D, Shibata H & Volk H 1977 L-phenylalanine mustard L-PAM ; in the management of primary breast cancer. An update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil 5-FU ; . Cancer 39 28832903. Fisher B, Redmond C, Dimitrov N, Bowman D, Legault-Poisson S, Wickerham D, Wolmark N, Fisher E, Margolese R & Sutherland C 1989 A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. New England Journal of Medicine 320 473478. Fisher B, Redmond B, Legault-Poisson S, Dimitrov N, Brown A, Wickerham D, Wolmark N, Margolese R, Bowman D & Glass A 1990 Postoperative chemotherapy and tamoxifen compared to tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years or older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. Journal of Clinical Oncology 8 1005 1018. Fisher B, Dignam J, DeCillis A, Wickerham D & Wolmark N 1996a Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen-receptor-positive tumors. Journal of the National Cancer Institute 88 15291542. Fisher B, Dignam J, Mamounas E, Costantino J, Wickerham D, Redmond C, Wolmark N, Dimitrov N, Bowman D, Glass A, Atkins J, Abramson N, Sutherland C, Aron B & Margolese R 1996b Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogenreceptor-negative tumors: eight year results from National Surgical Adjuvant Breast and Bowel Project NSABP ; B-13 and. In India, studies of mifepristone use outside of hospitals or specialty research clinics suggest the method can be provided safely and effectively in other settings. One study tested the use of mifepristone at a rural health facility in the village of Vadu Budhruk. A variety of health workers, including auxiliary nurse-midwives and "multipurpose" village workers, have been trained to provide abortion counseling and mifepristone treatment and follow-up under a doctor's supervision. The project proactively addressed some of the potential problems associated with mifepristone service delivery by ensuring that only early gestations were treated, providing adequate counseling about what to expect, identifying back-up facilities, and excluding remote villages from the service area. The project also reduced the number of clinic visits to three one to diagnose pregnancy and administer mifepristone, a second to administer misoprostol, and a third follow-up visit two weeks later ; . Interim results suggest that services provided in this setting are safe, effective, and highly acceptable to women.13 Metho5rexate plus prostaglandin. Methotrexate, an antimetabolite that interferes with cell division, has been used for many years as a treatment for ectopic pregnancy with effectiveness rates of 90 percent or higher; it is now being used by some to induce early abortion see Outlook, Volume 14, Number 2 and Volume 14, Number 3 ; . In women 49 days gestation or less, methotrexate generally is administered intramuscularly, 50 mg per square meter of body surface area, followed 5 to 7 days later by vaginal administration of 800 mcg of misoprostol. This regimen is 90 percent effective.14 A recent study evaluated use of 50 mg oral methotrexate followed 3 to 5 days later by 800 mcg vaginal misoprostol among 315 women. This regimen was 91 percent effective; no significant difference was found among women who received misoprostol three, four, or five days after administration of methotrexate.15 Side effects of these regimens include bleeding, cramping, nausea, vomiting, and diarrhea. One concern about methotrexate has been that the elapsed time between methotrexate administration and completion of abortion can be extended up to 30 days in some studies ; . The recent study of oral methotrexate plus vaginal misoprostol15 did not find this, however; all women in the study aborted within 24 hours of misoprostol administration. While some researchers believe that the methotrexate regimen should be made more widely available primarily because the drugs used in the regimen are low cost and readily available in many settings ; , others disagree. Because methotrexate is a known teratogen, a WHO Toxicology Panel has recommended against its use due to the potential for birth defects in infants born after treatment failure16 see Outlook, Volume 14, Number 3 ; . Given that up to ten percent of methotrexateinduced abortion attempts fail, and follow-up with surgical termination cannot be ensured in some settings, WHO scientists feel that the method cannot be recommended. Misoprostol. In addition to being used as a part of mifepristone or methotrexate regimens, misoprostol alone has been studied for induction of first and second trimester abortion as well as for treatment of missed abortion see box below ; . Self-medication with misoprostol to induce abortion appears to be a common practice in some countries, 17, 18 although dosages vary widely and there have been reports of misoprostol-associated heavy bleeding in some cases. While its low cost approximately US$ 2.00-6.00 per 800 mcg ; , widespread availability, and stability at room temperature similar drugs require refrigeration ; make it an attractive option, regimens studied to date are not as effective as other medical abortion choices. A study of 141 Cuban women of 10 weeks or less gestational age found that 83 percent aborted after a single treatment with misoprostol, though nearly half of these women had remaining uterine tissue that was surgically evacuated.19 The women self-inserted 800 mcg misoprostol vaginally, then remained recumbent for three hours. Further doses were administered if abortion did not occur within 48 hours. The failure rate was higher for women of gestational age greater than nine weeks 17 percent ; compared to women less than nine.
Werner Bollag Pharmaceutical Research F. Hoffmann-La Roche & Co. Ltd. CH-4002 Basel Switzerland August 22, 1988 I became interested in the relationship between vitamin A and cancer after intense literature studies, prompted by an article by U. Saffiotti eta!, in 1967 on inhibition oftracheobronchial carcinogenesis by 1 vitamin A. In the laboratories of Hoffmann-La Roche I observed that vitamin A exerted not only preventive but also therapeutic effects on chemically induced skin tumors of mice. The limitation for clinical use of vitamin A rested with its toxic side effects, known as hypervitaminosisA. Therefore, my working hypothesis wasas follows: By chemical manipulation of the vitamin A molecule, derivatives might be found, still possessing the desired preventive or therapeutic effect, but inducing fewer side effects. The first compound tested was the synthesized alltrans retinoic acid. Although this analog showed a better therapeutic index, this was far from satisfactory. By performing a lare synthetic program, my goal was to find analogs with a much more favorable ratio between tumor effect and toxicity. The Roche chemists, experienced in vitamin A chemistry, were in favor of the project. However, the vitamin biologists argued: "During millionsof years of evolution, nature has developed the best suhstance lookingfor a better one wouldbe hopeless." In reply, I discussed with them the analogy tothe field of steroids, where synthetic compounds had been found that displayed.

This newsletter, unless otherwise stated, applies to Medicare Choice members. PARTNERS is committed to offering its health plans on a non-discriminatory basis. PARTNERS does not discriminate based on color, religion, national origin, age, race, disability, handicap, gender, or health status as defined by CMS. PARTNERS National Health Plans of North Carolina, Inc. Provider Services 336-774-5400 or 1-888-296-9790.